BACKGROUND: This study examined whether oral misoprostol exerted a cervical priming effect in postmenopausal women prior to hysteroscopy. METHOD: Thirty-seven patients were randomized to receive either oral misoprostol (400 µg) or placebo (vitamin B 6 ) 12 h prior to hysteroscopy. The resistance of the cervix to dilatation was objectively assessed by a cervical tonometer. RESULTS: The mean baseline cervical dilatation (4.2 mm in misoprostol group versus 4.4 mm in placebo group) was similar between the two groups. The mean cumulative force measured (27.7 N in misoprostol group versus 21.8 N in placebo group) was also comparable. None of the patients suffered from any significant side-effects. CONCLUSIONS: These data showed that there were no significant benefits from giving misoprostol pre-operatively in postmenopausal women, and it was concluded that oral misoprostol had no significant cervical priming effect in postmenopausal women.
Introduction randomized trial in Queen Mary Hospital. Subjects participating in
Postmenopausal bleeding is a common gynaecological this trial were recruited from women who had a definite indication problem. Endometrial biopsy is often necessary to exclude for hysteroscopy and endometrial sampling. The inclusion criteria endometrial carcinoma. The procedure is sometimes difficult included: (i) good general health; (ii) menopause (amenorrhoea for because of the small and tight cervical os in postmenopausal Ͼ12 months); and (iii) willingness to participate after the study had women. Sometimes the patients need to undergo hysteroscopy been explained. Women with a history of past ill health were excluded and endometrial sampling for a formal assessment. from the recruitment. None of the recruited patients was on hormonal Difficulty in negotiating through the cervical os is not replacement therapy.
uncommon. The procedure may be abandoned even when it Women were randomized into two groups: group 1, placebo is performed under general anaesthesia. Cervical injuries, (vitamin B 6 ); group 2, 400 µg of oral misoprostol. The randomization uterine perforation, creation of a false tract or haemorrhage schedule was produced as described by Meinert (Meinert, 1986) . The may occur. Unfortunately, data concerning the effectiveness tablets were put into a plastic bag labelled with subject number of cervical priming agent in postmenopausal women are according to the randomization schedule at the pharmacy in Queen Mary Hospital.
lacking. This is of particular importance, especially if office Women who were recruited underwent a full medical, obstetrical hysteroscopy is to be used. , 1997) . It is safe, well tolerated and inexpensive. As data Bioengineering, UK) was used to measure the peak force required to for the use of this drug in postmenopasal women were lacking, enter the cervical os with successive dilators from 2-6 mm. The a randomized study was performed to investigate the cervical resistance of cervix to dilatation was objectively assessed using a priming effect of misoprostol in this group. series of tapered dilators attached to a force-sensing handle as described previously (El-Rafaey et al., 1994) . Baseline dilatation was
Materials and methods
defined as the first dilator, which required a peak force Ͼ5 N to enter the internal os. The cumulative force required to dilate the cervix Ethical approval for the study was granted by the Ethics Committee, Queen Mary Hospital. A total of 37 women admitted for hysteroscopy was calculated by summing the peak forces produced by each dilator forms if complications occurred. All women were followed up 6 weeks later. The calculation of the sample size was based on the following assumptions: (i) type 1 error of 0.05 and power of 0.8 were acceptable Table III . Pre-operative side-effects in misoprostol and placebo groups.
and (ii) it was assumed that the baseline cervical dilatation was 1 mm
Values are shown as number (%) in the postmenopausal women and a change of 2 mm in baseline dilatation would be significant in clinical management. The ideal Misoprostol Placebo sample size in each group was calculated as 17, and to allow for n ϭ 18 n ϭ 16 10% of the data being unusable, the number in each group was set at 19. Therefore, the total sample size was 38. Nausea 1 (5.6) 0
The characteristics of the subjects, the indication for dilatation and required for the procedure was also comparable (27.7 N in misoprostol group versus 21.8 N in placebo group).
Results
As the patients in the placebo group were significantly older There was a change in treatment policy in our department when compared with the misoprostol group, we have compared after recruitment of 37 women and nearly all the hysteroscopy the cumulative force within the former group. There was no procedures were performed under local anaesthesia. Therefore, significant difference in cumulative force between those whose the project was terminated when a total of 37 postmenopausal age was ഛ65 years (median age) versus Ͼ65 years within the women had been recruited. Three women did not have cumulatplacebo group (26.9 N versus 19.2 N respectively). Similarly, ive force and baseline cervical dilatation recorded because (i) there was no difference in baseline dilatation and duration of the the machine malfunctioned (n ϭ 1), (ii) the operation was operation between the two groups. Therefore, age differences changed to local anaesthesia (n ϭ 1), and (iii) the procedure between the misoprostol and placebo groups probably would was delayed and performed by another surgeon (n ϭ 1). All not affect the ease of dilatation. The duration of the procedure of the study subjects underwent the operation without suffering as well as the blood loss was comparable between the two from any complication.
groups. No operative complications were encountered in any Patients' characteristics are shown in Table I . The median subjects. The pre-operative side-effects are shown in Table III . age of subjects in the misoprostol group was significantly Gastrointestinal symptoms were uncommon and mild in both lower than that of the placebo group (55.6 versus 66.9 years, groups. The incidence was low and comparable between the P ϭ 0.01). In the placebo group, the patients' ages ranged two groups. from 47 to 86 years whereas in the misoprostol group, they ranged from 49 to 67 years. Other demographic parameters, Discussion including body weight, height and body mass index, were comparable between the two groups. Operative findings are Cervical ripening is a complicated process, being mediated by hormones, cytokines, growth factors and other biochemical summarized in Table II . The mean baseline cervical dilatation was similar between the two groups (4.2 mm in misoprostol compounds (Barclay et al., 1993; Norman et al., 1993) . Misoprostol had been shown to be effective for cervical group versus 4.4 mm in placebo group). Cumulative force priming in pregnant women (Ngai et al., 1995 (Ngai et al., , 1996 (Ngai et al., , 1999 .
knowledge of the biochemistry and ultrastructure of the human cervix will most likely be of practical importance in the Information on the use of prostaglandins in non-pregnant cervix was scanty. With the introduction of various hysteroscopic near future. Further laboratory basic research on the local concentration, action and interaction of gonadal steroids and procedures, it was considered worthwhile to explore the role of cervical priming in this group of women.
prostaglandins, and their effects on collagenase and noncollagenolytic proteases in the cervical ripening process are We have previously demonstrated that 400 µg oral misoprostol, when given 12 h prior to hysteroscopy, reduced cervical awaited to confirm or refute the speculation stated above. resistance significantly when compared with placebo (Ngai et al., 1997) . In that study, subjects suffered from infertility
